Loading stock data…
PRFX
$1.89-0.04 (-2.07%)
Market ClosedLast close May 1
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PRF Technologies Ltd. in the Healthcare sector is trading at $1.89. The stock is currently near its 52-week low of $1.80, remaining 61.3% below its 200-day moving average. Technical signals show oversold RSI of 11 and bearish MACD signal, explaining why PRFX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 11) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.89
Potential Upside
5%
Whystock Fair Value$1.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-86.14%
Volume
Today's trading volume
13,007
Recent News
EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain
The U.S. Food and Drug Administration (FDA) on Tuesday cleared PRF Technologies Ltd.'s Investigational New Drug application for OcuRing-K, enabling the company to move into a Phase 2 trial targeting pain and inflammation following cataract surgery. The milestone advances PRF's strategy to develop a sustained-release, drop-less therapy aimed at simplifying post-operative care. The company is focused on the reformulation of established therapeutics and developing AI-driven energy optimization tech
BC-Most Active Stocks
Gibo Holdings Ltd. 62,940,523 0.0274